Clinical Trials Logo

Neuroendocrine Carcinomas clinical trials

View clinical trials related to Neuroendocrine Carcinomas.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04122911 Completed - Clinical trials for Neuroendocrine Carcinomas

Temozolomide for Second-Line Treatment of Neuroendocrine Carcinomas

TENEC
Start date: January 29, 2017
Phase: Phase 2
Study type: Interventional

To assess the efficacy and safety of Temozolomide for second-line treatment of Neuroendocrine Carcinomas progressing after first-line Platinum-based therapy.

NCT ID: NCT02457273 Completed - Clinical trials for Neuroendocrine Carcinomas

Phase II Study to Evaluate the Efficacy and Safety of TLC388 for Differentiated Neuroendocrine Carcinomas Patients

Start date: July 4, 2015
Phase: Phase 2
Study type: Interventional

Title of Study: An Open-Label, Single-Arm, Two-Stage, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of TLC388 as Second-line Treatment in Subjects with Poorly Differentiated Neuroendocrine Carcinomas Investigational product: Lipotecan®* *Lipotecan® is the trade name of TLC388 HCl, a Topoisomerase I inhibitor) Phase of development: Phase II Number of subjects: Plan to enroll 44 subjects Objectives: Primary objectives: To determine the objective response rate Secondary objectives: To evaluate Disease control rate, Progression free survival, Overall survival, Safety profile and Biomarkers